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Abstract
Objective: In this study, we determined circulating levels of C-reactive protein, several cytokines, chemokines,
adhesion molecules and angiogenic factors along with those of leptin in healthy non-pregnant and pregnant
women and preeclamptic patients, and investigated whether serum leptin levels were related to the clinical
characteristics and measured laboratory parameters of the study participants.
Methods: Sixty preeclamptic patients, 60 healthy pregnant women and 59 healthy non-pregnant women were
involved in this case-control study. Levels of leptin and transforming growth factor (TGF)-beta1 in maternal sera
were assessed by ELISA. Serum levels of interleukin (IL)-1beta, IL-1 receptor antagonist (IL-1ra), IL-2, IL-4, IL-6, IL-8, IL-
10, IL-12p40, IL-12p70, IL-18, interferon (IFN)-gamma, tumor necrosis factor (TNF)-alpha, interferon-gamma-inducible
protein (IP)-10, monocyte chemotactic protein (MCP)-1, intercellular adhesion molecule (ICAM)-1 and vascular cell
adhesion molecule (VCAM)-1 were determined by multiplex suspension array. Serum C-reactive protein (CRP)
concentrations were measured by an autoanalyzer. Serum total soluble fms-like tyrosine kinase-1 (sFlt-1) and
biologically active placental growth factor (PlGF) levels were determined by electrochemiluminescence
immunoassay. For statistical analyses, non-parametric methods were applied.
Results: There were significant differences in most of the measured laboratory parameters among the three study
groups except for serum IL-1beta and TGF-beta1 levels. Serum leptin levels were significantly higher in
preeclamptic patients and healthy pregnant women than in healthy non-pregnant women. Additionally,
preeclamptic patients had significantly higher leptin levels as compared to healthy pregnant women. Serum leptin
levels were independently associated with BMI in healthy non-pregnant women. In healthy pregnant women, both
BMI and serum CRP concentrations showed significant positive linear association with leptin levels. There were
significant positive correlations between serum leptin concentrations of healthy pregnant women and systolic
blood pressure, as well as serum levels of IP-10, while their serum leptin levels correlated inversely with fetal birth
weight. In preeclamptic patients, a significant positive correlation was observed between serum concentrations of
leptin and IP-10. Furthermore, elevated serum leptin level and sFlt-1/PlGF ratio had an additive (joint) effect in the
risk of preeclampsia, as shown by the substantially higher odds ratios of their combination than of either alone.
Conclusions: Simultaneous measurement of leptin with several inflammatory molecules and angiogenic factors in
this study enabled us to investigate their relationship, which can help to understand the role of circulating leptin
in normal pregnancy and preeclampsia.
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Background
Preeclampsia, characterized by hypertension and pro-
teinuria developing after the 20th week of gestation in
a previously normotensive woman, is a severe compli-
cation of human pregnancy with a worldwide incidence
of 2-10%. It is one of the leading causes of maternal, as
well as perinatal morbidity and mortality, even in
developed countries. Despite extensive research, the
etiology and pathogenesis of preeclampsia are not
completely understood. There is an increasing body of
evidence that an exaggerated maternal systemic inflam-
matory response to pregnancy with activation of both
the innate and the adaptive arms of the immune sys-
tem plays a central role in the pathogenesis of the dis-
ease [1,2]. The excessive production of pro-
inflammatory cytokines, chemokines and adhesion
molecules may trigger a generalized endothelial dys-
function characteristic of the maternal syndrome of
preeclampsia [3]. In addition, an imbalance between
angiogenic and anti-angiogenic factors has also been
implicated in the development of this multifactorial
disorder [4-6].
Leptin is a peptide hormone of 16 kDa molecular
weight comprising 167 amino acids. The major source
of leptin is the adipose tissue, but it can also be pro-
duced by other organs, including the placenta [7]. This
anti-obesity hormone decreases food intake and
increases energy expenditure, thereby reducing body
weight and adiposity [8]. It also modulates glucose
metabolism by increasing insulin sensitivity [9] and acti-
vates the sympathetic nervous system [10,11]. Further-
more, leptin has been implicated in the control of the
reproductive function, including embryonic development
and implantation [12]. Leptin can also be considered as
a pro-inflammatory cytokine that belongs to the type I
cytokine superfamily and has structural similarity with
interleukin-6 [13]. Increasing evidence suggests that lep-
tin is involved in the regulation of innate and adaptive
immune responses and inflammation [14]. Circulating
leptin levels are significantly higher in pregnant than in
non-pregnant women [7,15], and there is a further
increase in complicated pregnancies, such as gestational
diabetes mellitus, preeclampsia and intrauterine growth
restriction [16-20].
In the present study, we determined serum leptin
levels in a large number of healthy non-pregnant and
pregnant women and preeclamptic patients. We also
measured circulating levels of C-reactive protein and
several cytokines, chemokines, adhesion molecules and
angiogenic factors in a comprehensive manner, and
investigated whether serum leptin levels were related to
the clinical characteristics and measured laboratory
parameters of the study participants.
Methods
Study patients
Our study was designed as a case-control study. Sixty
preeclamptic patients, 60 healthy pregnant women with
uncomplicated pregnancies and 59 healthy non-pregnant
women were involved in the study. The study partici-
pants were enrolled in the First Department of Obste-
trics and Gynecology and in the Department of
Obstetrics and Gynecology of Kútvölgyi Clinical Center,
at the Semmelweis University, Budapest, Hungary. All
women were Caucasian and resided in the same geo-
graphic area in Hungary. The preeclamptic patients and
healthy pregnant women were matched on the basis of
maternal age and gestational age at blood draw, and
they were selected accordingly from the previously
reported groups of 93 preeclamptic patients and 176
healthy pregnant women [21,22]. Exclusion criteria were
multifetal gestation, chronic hypertension, diabetes mel-
litus, autoimmune disease, angiopathy, renal disorder,
maternal or fetal infection and fetal congenital anomaly.
None of the pregnant women were in active labor, and
none had rupture of membranes. The healthy non-preg-
nant women were consecutively selected in the early fol-
licular phase of their menstrual cycle (between cycle
days 3 and 5), and none of them received hormonal
contraception.
Preeclampsia was defined by increased blood pressure
(≥140 mmHg systolic or ≥90 mmHg diastolic on ≥2
occasions at least 6 hours apart) that occurred after the
20th week of gestation in a woman with previously nor-
mal blood pressure, accompanied by proteinuria (≥0.3 g/
24 h or ≥1 + on dipstick in the absence of urinary tract
infection). Blood pressure returned to normal by the
12th postpartum week in each preeclamptic study
patient. Preeclampsia was regarded as severe if any of
the following criteria was present: blood pressure≥160
mmHg systolic or ≥110 mmHg diastolic, or protei-
nuria≥5 g/24 h (or ≥3 + on dipstick). Pregnant women
with eclampsia or HELLP syndrome (hemolysis, elevated
liver enzymes, and low platelet count) were not enrolled
in this study. Early onset of preeclampsia was defined as
onset of the disease before the 34th week of gestation
(between the 20th and 33rd completed gestational
weeks). Intrauterine growth restriction (IUGR) was diag-
nosed if the fetal birth weight was below the 10th per-
centile for gestational age and gender, based on
Hungarian birth weight percentiles [23].
The study protocol was approved by the Regional and
Institutional Committee of Science and Research Ethics
of the Semmelweis University, and written informed
consent was obtained from each patient. The study was
conducted in accordance with the Declaration of
Helsinki.
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Biological samples
Fasting blood samples were taken from an antecubital
vein into plain tubes, and then centrifuged at room tem-
perature with a relative centrifugal force of 3000 g for 10
minutes. The aliquots of serum were stored at -80°C
until the analyses.
Laboratory methods
Levels of leptin and transforming growth factor (TGF)-
b1 in maternal sera were assessed by ELISA (DRG Inter-
national, Mountainside, New Jersey, USA, Cat. No. EIA-
2395 and EIA-1864, respectively). Serum levels of inter-
leukin (IL)-1b, IL-1 receptor antagonist (IL-1ra), IL-2,
IL-4, IL-6, IL-8, IL-10, IL-12p40, IL-12p70, IL-18, inter-
feron (IFN)-g, tumor necrosis factor (TNF)-a, inter-
feron-g-inducible protein (IP)-10, monocyte chemotactic
protein (MCP)-1, intercellular adhesion molecule
(ICAM)-1 and vascular cell adhesion molecule (VCAM)-
1 were determined by multiplex suspension array on a
Bio-Plex 200 analyzer (Bio-Rad Laboratories, Hercules,
California, USA). We diluted the serum 1:4 in sample
diluent. The samples were measured at low Photomulti-
plier Tube (PMT) setting according to the instructions
provided in the assay manual. The assays were per-
formed using the Bio-Plex filter plates and manual
vacuum manifold. We applied the Bio-Plex Manage-
r™software. A 10-point extended broad range standard
curve was used in order to maximize sensitivity for sam-
ples that have very low levels of analytes. Any high end
saturation points were removed from the standard
curves for determining sample concentrations. Serum C-
reactive protein (CRP) concentrations were measured by
an autoanalyzer (Cobas Integra 800, Roche, Mannheim,
Germany) using the manufacturer’s kit. Serum total
soluble fms-like tyrosine kinase-1 (sFlt-1) and biologi-
cally active placental growth factor (PlGF) levels were
determined by electrochemiluminescence immunoassay
(Elecsys, Roche, Mannheim, Germany, Cat. No.
05109523 and 05144671, respectively) on a Cobas e 411
analyzer (Roche, Mannheim, Germany).
Statistical analysis
The normality of continuous variables was assessed
using the Shapiro-Wilk’s W-test. As the continuous vari-
ables were not normally distributed, non-parametric sta-
tistical methods were used. To compare continuous
variables between two groups, the Mann-Whitney U-
test was applied, whereas to compare them among mul-
tiple groups, the Kruskal-Wallis analysis of variance by
ranks test was performed. Multiple comparisons of
mean ranks for all groups were carried out as post-hoc
tests. The Fisher exact and Pearson c2 tests were used
to compare categorical variables between groups. The
Spearman rank order correlation was applied to
calculate correlation coefficients. Analysis of covariance
(ANCOVA) and multiple linear regression analyses were
undertaken, as a non-parametric method, with logarith-
mically transformed values of serum leptin concentra-
tions. Odds ratios (OR) with 95% confidence intervals
(CI) were calculated by logistic regression. For all statis-
tical analyses, p < 0.05 was considered statistically
significant.
In the article, data are reported as median (interquar-
tile range) for continuous variables and as number (per-
centage) for categorical variables.
Results
Patient characteristics
The clinical characteristics of the study participants are
described in Table 1. There was no statistically significant
difference in terms of age among the study groups.
Furthermore, no significant differences were observed in
gestational age at blood collection and the percentage of
primiparas between preeclamptic patients and healthy
pregnant women. However, all of the other clinical fea-
tures presented in Table 1, including smoking status, dif-
fered significantly among our study groups. Fetal growth
restriction was absent in healthy pregnant women,
whereas the frequency of this condition was 18.3% in the
preeclamptic group. Doppler abnormalities were
observed in 7 fetuses of preeclamptic mothers (11.7%).
Twenty-one women (35.0%) had severe preeclampsia and
5 patients (8.3%) experienced early onset of the disease.
Laboratory parameters
The laboratory parameters of the study subjects are dis-
played in Figure 1 and 2. As can be seen in the figures,
there were significant differences in most of the mea-
sured laboratory parameters among the three study
groups except for serum IL-1b and TGF-b1 levels. As
shown in Figure 1, serum leptin levels were significantly
higher in preeclamptic patients and healthy pregnant
women than in healthy non-pregnant women. Further-
more, preeclamptic patients had significantly higher lep-
tin levels as compared to healthy pregnant women. The
differences remained significant even after adjustment
for BMI at blood draw in ANCOVA.
In the group of preeclamptic patients, no statistically
significant differences were found in serum leptin con-
centrations between patients with mild and severe pree-
clampsia, between patients with late and early onset of
the disease, or between preeclamptic patients with and
without fetal growth restriction (data not shown).
Relationship of serum leptin levels of the study subjects
to their clinical characteristics and laboratory parameters
We also investigated whether serum leptin levels of the
study participants were related to their clinical features
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and laboratory parameters by calculating the Spearman
rank order correlation coefficients (continuous variables)
or by the Mann-Whitney U-test (categorical variables).
In healthy non-pregnant women, serum leptin concen-
trations correlated significantly with body mass index
(BMI) and serum CRP levels (Spearman R = 0.59, p <
0.001 and 0.39, p < 0.05, respectively). However, in mul-
tiple linear regression analysis, only the association
between leptin levels and BMI remained significant
(standardized regression coefficient (b) = 0.53, p <
0.001). In the group of healthy pregnant women, we
found statistically significant positive correlations
between serum leptin concentrations and BMI (R =
0.49, p < 0.001), systolic blood pressure (R = 0.38, p <
0.05), as well as serum levels of CRP (R = 0.46, p <
0.05), IL-6 (R = 0.35, p < 0.05) and IP-10 (R = 0.31, p <
0.05). In a multiple linear regression model involving
BMI, serum CRP and IL-6 levels as independent vari-
ables, both BMI and serum CRP concentrations showed
significant positive linear association with leptin levels in
healthy pregnant women (b = 0.43 and 0.45, respec-
tively, p < 0.05 for both). There was a significant inverse
correlation between serum leptin concentrations of
healthy pregnant women and fetal birth weight (R =
-0.36, p < 0.05), even after adjustment for gestational
age at delivery in multiple linear regression analysis (b =
-0.51, p < 0.001). In the preeclamptic group, a signifi-
cant positive correlation was observed between serum
levels of leptin and IP-10 (R = 0.36, p < 0.05). There
was no other relationship between serum leptin concen-
trations of the study subjects and their clinical features
and measured laboratory parameters in either study
group.
Using the Receiver Operating Characteristic (ROC)
curve analysis (Figure 3), we determined cut-off values
for serum leptin concentration (> 74.3 ng/ml, sensitivity:
57.6%, specificity: 84.7%; area under curve (AUC) with
95% CI: 0.72 (0.63-0.80)) and sFlt-1/PlGF ratio (> 31.2,
sensitivity: 75.9%, specificity: 74.1%; AUC (95% CI): 0.81
(0.73-0.88)) to discriminate preeclamptic patients from
healthy pregnant women. In a multiple logistic regres-
sion model involving both variables, elevated serum lep-
tin level and sFlt-1/PlGF ratio were found to be
independent predictors of preeclampsia (odds ratios
Table 1 Clinical characteristics of healthy non-pregnant and pregnant women and preeclamptic patients
Healthy non-pregnant women
(n = 59)
Healthy pregnant women
(n = 60)
Preeclamptic patients
(n = 60)
Age (years) 28 (23-35) 30 (28-32) 29 (26-32)
Pre-pregnancy BMI (kg/m2) n.a. 21.0 (19.5-22.6) 25.5 (21.6-28.1)d
BMI at blood draw (kg/m2) 20.8 (19.6-22.9) 25.8 (24.3-27.9)b 29.9 (26.9-33.3)b, d
Smokers 14 (23.7%) 0 (0%)b 3 (5.0%)a
Primiparas n.a. 37 (61.7%) 38 (63.3%)
Systolic blood pressure at blood draw (mmHg) 115 (110-120) 110 (107-120) 162 (155-180)b, d
Diastolic blood pressure at blood draw (mmHg) 80 (70-80) 70 (60-80)b 100 (97-110)b, d
Gestational age at blood draw (weeks) n.a. 36 (36-37) 37 (36-39)
Gestational age at delivery (weeks) n.a. 39 (38-40) 38 (37-39)d
Fetal birth weight (grams) n.a. 3450 (3150-3700) 3125 (2450-3475)d
Fetal growth restriction n.a. 0 (0%) 11 (18.3%)d
Data are presented as median (interquartile range) for continuous variables and as number (percentage) for categorical variables
n.a.: not applicable; BMI: body mass index
a p < 0.05 versus healthy non-pregnant women
b p < 0.001 versus healthy non-pregnant women
c p < 0.05 preeclamptic patients versus healthy pregnant women
d p < 0.001 preeclamptic patients versus healthy pregnant women
Figure 1 Serum leptin levels of healthy non-pregnant and
pregnant women and preeclamptic patients. Middle point:
median; Box: interquartile range (25-75 percentile); Whisker: range
(excluding outliers). a p < 0.001 versus healthy non-pregnant
women; b p < 0.001 preeclamptic patients versus healthy pregnant
women.
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Figure 2 Serum levels of C-reactive protein, cytokines, chemokines, adhesion molecules and angiogenic factors in healthy non-
pregnant and pregnant women and preeclamptic patients. Middle point: median; Box: interquartile range (25-75 percentile); Whisker: range
(excluding outliers). CRP: C-reactive protein; IL: interleukin; IL-1ra: IL-1 receptor antagonist; IFN: interferon; TNF: tumor necrosis factor; TGF:
transforming growth factor; IP: interferon-g-inducible protein; MCP: monocyte chemotactic protein; ICAM: intercellular adhesion molecule; VCAM:
vascular cell adhesion molecule; sFlt: soluble fms-like tyrosine kinase; PlGF: placental growth factor. a p < 0.05 versus healthy non-pregnant
women; b p < 0.001 versus healthy non-pregnant women; c p < 0.05 preeclamptic patients versus healthy pregnant women; d p < 0.001
preeclamptic patients versus healthy pregnant women.
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with 95% confidence intervals: 9.16 (3.16-26.5) and 8.89
(3.34-23.7), respectively, p < 0.001 for both; after adjust-
ment for BMI at blood draw: 5.03 (1.48-17.1), p < 0.05
and 11.3 (3.24-39.2), p < 0.001, respectively). Women
with elevated serum leptin level and sFlt-1/PlGF ratio
had substantially higher odds for having preeclampsia
than those with elevated sFlt-1/PlGF ratio or serum lep-
tin concentration alone (OR (95% CI): 80.5 (14.4-450), p
< 0.001 versus 9.0 (2.80-29.0), p < 0.001 and 9.33 (2.27-
38.4), p < 0.05, respectively), even after adjustment for
BMI at blood collection in multiple logistic regression
analyses (adjusted OR (95% CI): 65.9 (9.47-459), p <
0.001 versus 6.91 (1.55-30.7), p < 0.05 and 1.42 (0.15-
13.0), p > 0.05, respectively).
Discussion
In this study, we measured circulating levels of C-reac-
tive protein, several cytokines, chemokines, adhesion
molecules and angiogenic factors along with those of
leptin in healthy non-pregnant and pregnant women
and preeclamptic patients. According to our findings,
serum leptin levels were independently associated with
BMI in healthy non-pregnant women. In healthy preg-
nant women, both BMI and serum CRP concentrations
showed significant positive linear association with leptin
levels. There were significant positive correlations
between serum leptin concentrations of healthy preg-
nant women and systolic blood pressure, as well as
serum levels of IP-10, while their serum leptin levels
correlated inversely with fetal birth weight. In pree-
clamptic patients, a significant positive correlation was
observed between serum concentrations of leptin and
IP-10. Furthermore, the combination of elevated serum
leptin level and sFlt-1/PlGF ratio was found to be addi-
tive for the risk of preeclampsia.
Leptin was first introduced as an adipocyte-derived
signal of energy metabolism [24]. Indeed, the indepen-
dent association of serum leptin levels with BMI in our
healthy non-pregnant and pregnant women indicates
that adipose tissue is a major source of circulating lep-
tin. Later on, the placenta has been demonstrated to be
an alternative source of leptin in the maternal circula-
tion [7,25]. Maternal serum leptin levels have been
reported to increase during the course of a normal preg-
nancy with a peak at around 20-30 weeks of gestation
and to decrease rapidly after birth [26-28]. In addition
to BMI, serum levels of CRP were also directly related
to those of leptin in our healthy pregnant group (unlike
in non-pregnant women [29]), suggesting that systemic
inflammation characteristic of the third trimester of nor-
mal pregnancy might contribute to the increase in circu-
lating leptin levels. In fact, inflammatory stimuli,
including pro-inflammatory cytokines, can induce the
expression of leptin and increase its serum level [30-32].
Therefore, the elevation of maternal circulating leptin
levels in normal pregnancy could reflect - at least in
part - an increase in adipocyte/trophoblast leptin synth-
esis mediated by inflammatory stimuli. On the contrary,
serum leptin levels were found to increase indepen-
dently from BMI and CRP in our preeclamptic group, as
shown by the lack of correlations with these variables.
Interestingly, placental expression of leptin has been
observed to be raised in preeclampsia by several
research groups, including ours [17,33-37]. An increas-
ing body of evidence suggests that placental insufficiency
and resultant placental hypoxia might be responsible for
augmented placental production of leptin in this preg-
nancy-specific disorder, leading to its elevated concen-
tration in the maternal circulation [17,38-41].
Leptin is a pleiotropic molecule, which has also been
implicated in the regulation of innate and adaptive
immune responses by several ways [14,42]. This mole-
cule alters the balance of T cell-derived cytokines in
favour of a Th1-type response [43,44]. Leptin can also
induce pro-inflammatory cytokine production of mono-
cytes/macrophages [45,46]. It is noteworthy that the
maternal syndrome of preeclampsia is characterized by a
predominant Th1-type immune response with elevated
amounts of pro-inflammatory molecules in the maternal
circulation [3,47,48]. However, in this study, we did not
find any association between serum levels of leptin and
pro-inflammatory cytokines in preeclampsia, which
might be explained - at least partly - by the fact that the
Figure 3 Receiver Operating Characteristic (ROC) curves. Serum
leptin levels (leptin, continuous line) and soluble fms-like tyrosine
kinase-1 to placental growth factor ratio (sFlt-1/PlGF ratio, dashed
line) to discriminate between preeclamptic patients and healthy
pregnant women.
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latter (especially TNF-a and IL-1b) have a very short
half- life in the maternal circulation. Leptin may also be
involved in blood pressure regulation through its central
effect on sympathetic activity [10,11,49]. Accordingly,
there was a significant positive correlation between
serum leptin concentrations and systolic blood pressure
in our healthy pregnant women. Nevertheless, the lack
of relationship between leptin levels and blood pressure
values in our preeclamptic group indicates that the pro-
cess responsible for blood pressure elevation in this
multifactorial disease is more complex and involves the
interplay of numerous factors in addition to the sympa-
thetic action of leptin.
An intriguing finding of our study is that increased
serum levels of leptin were related to those of interferon-
g-inducible protein (IP)-10 both in normal pregnancy
and preeclampsia, as shown by the significant correla-
tions between these variables. This is consistent with the
in vitro observation that leptin selectively induces the
expression and secretion of IP-10 in human monocytic
cells [50]. IP-10 (CXCL10) has pro-inflammatory and
anti-angiogenic properties, and this chemokine has been
proposed to be a potential link between inflammation
and anti-angiogenesis in preeclampsia [51]. In our pre-
vious study, IP-10 showed the strongest association with
markers of endothelial dysfunction, as well as with renal
and liver function parameters in healthy pregnant
women and preeclamptic patients [3]. Therefore, it is
tempting to speculate that IP-10 might play a connecting
role between elevated circulating leptin levels and the
generalized endothelial dysfunction characteristic of pre-
eclampsia. On the other hand, leptin can promote angio-
genesis at least partly through the up-regulation of
vascular endothelial growth factor expression in endothe-
lial cells [52,53]. Nevertheless, increased levels of anti-
angiogenic factors such as sFlt-1 in the maternal circula-
tion in normal pregnancy and preeclampsia might blunt
this beneficial direct effect of leptin on angiogenesis.
Another remarkable observation of this study is that
serum leptin levels correlated inversely with fetal birth
weight in the group of healthy pregnant women. In pre-
vious studies, elevated circulating leptin levels have been
found in mothers with fetal growth restriction [18,19].
This relationship might reflect the state of inflammation
and chronic stress in IUGR mothers. As reduced uteropla-
cental blood flow plays an important role in the pathogen-
esis of IUGR, resultant placental hypoxia might also
account for the observed increase in maternal circulating
leptin levels. Indeed, leptin expression was up-regulated in
placental tissues of IUGR neonates [54]. Furthermore,
maternal first trimester plasma leptin levels negatively cor-
related with birth weight among normotensive and pree-
clamptic women [55]. Interestingly, we have recently
detected an inverse correlation between IP-10 levels and
fetal birth weight in healthy pregnant women, which raises
the possibility that maternal leptin levels could influence
fetal growth in normal pregnancy - at least in part -
through the inhibitory effect of IP-10 on placental angio-
genesis. Nevertheless, preeclampsia may disrupt the asso-
ciation of maternal leptin levels with fetal growth, as
shown by the lack of correlation with birth weight in our
preeclamptic group. On the contrary, a recent meta-analy-
sis demonstrated that cord blood leptin concentrations of
small-for-gestational-age newborns are significantly lower
than those of appropriate-for-gestational-age newborns
[56]. Additionally, fetal circulating leptin levels positively
correlate with birth weight in normal pregnancy [15,57].
In fact, leptin seems to play a crucial role in fetal growth
[58], and it might be a potential link between poor fetal
growth and the subsequent development of chronic dis-
eases in later life [59].
Accumulating data indicate a central role of circulat-
ing angiogenic factors and their antagonists in the
pathogenesis of preeclampsia [4-6]. In this study, we
also measured serum sFlt-1 and PlGF concentrations in
normal pregnancy and preeclampsia by electrochemilu-
minescence immunoassay. However, increased sFlt-1
and decreased PlGF levels were not related to serum
leptin concentrations in women with preeclampsia, sug-
gesting that alterations in angiogenic cytokine profile
and circulating levels of leptin are independent mechan-
isms in the pathogenesis of this multifactorial disorder.
Instead, elevated serum leptin level and sFlt-1/PlGF
ratio had an additive (joint) effect in the risk of pree-
clampsia, as shown by the substantially higher odds
ratios of their combination than of either alone.
In our study, the similar circulating leptin concentra-
tions of preeclamptic patients regardless of the severity,
the time of onset of the disease or the presence of fetal
growth restriction might be explained by the multifactor-
ial etiology of preeclampsia. Several genetic, behavioural
and environmental factors need to interact to produce
the complete picture of this pregnancy-specific disorder.
Our research group reported various genetic (including
leptin receptor gene polymorphisms) and soluble factors
that were associated with the severity or complications of
preeclampsia [60-63]. Nevertheless, it is also possible that
the relatively small sample size of this study prevented to
detect an effect in the subgroup analyses.
Simultaneous measurement of leptin with C-reactive
protein, several cytokines, chemokines, adhesion mole-
cules and angiogenic factors in this study enabled us to
investigate their relationship, which can help to under-
stand the role of circulating leptin in normal pregnancy
and preeclampsia. Elevated leptin concentration in the
first trimester of pregnancy appears to be associated
with an increased risk of developing preeclampsia later
in gestation [55,64,65]. Given the case-control design of
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our study, we could not confirm this association.
Further longitudinal studies are required to clarify the
predictive value of circulating leptin in preeclampsia.
Conclusions
Elevated serum leptin concentrations were associated with
the mass of adipose tissue, systemic inflammation and sys-
tolic blood pressure, as well as negatively with birth weight
in the third trimester of normal pregnancy. In addition,
increased serum levels of leptin were related to those of
interferon-g-inducible protein (IP)-10 both in normal
pregnancy and preeclampsia, suggesting that circulating
leptin might contribute to the development of endothelial
dysfunction and poor fetal growth through the anti-angio-
genic effect of IP-10. Moreover, the combination of ele-
vated serum leptin level and sFlt-1/PlGF ratio was found
to be additive for the risk of preeclampsia.
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